New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 6, 2014
07:21 EDTVRX, AGNValeant recent weakness a buying opportunity, says JPMorgan
JPMorgan recommends using the recent pullback in shares of Valeant (VRX) as a buying opportunity. After meeting with management, the firm has increased confidence in the company's ability to show accelerating top-line growth in the second half of 2014. It sees "compelling value" in Valeant shares regardless of the Allergan (AGN) outcome and keeps an Overweight rating on the stock with a $180 price target.
News For VRX;AGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 9, 2014
06:47 EDTAGNAllergan sees FY15 non-GAAP EPS $8.60, consensus $8.25
Subscribe for More Information
06:47 EDTAGNAllergan sees FY14 non-GAAP EPS $6.20-$6.25, consensus $5.81
Subscribe for More Information
06:46 EDTAGNAllergan raises Q3 EPS to $1.76-$1.78 from $1.44-$1.47, consensus $1.48
Expects Q3 product net sales to increase in excess of 17% in dollars compared to product net sales from 3Q13.
October 8, 2014
16:10 EDTAGNAllergan initiated with a Buy at Deutsche Bank
Subscribe for More Information
08:42 EDTAGNSalix shares should be bought on weakness, says Sterne Agee
After Reuters yesterday afternoon reported that Actavis (ACT) plans to make a new merger approach to Allergan (AGN), Sterne Agee believes that Salix's standalone value is $162. The firm expects the shares to reach that level following approval of its Xifaxan IBS-D drug after the February 2015 PDUFA date.
07:19 EDTAGNCBI to hold a conference
Subscribe for More Information
06:23 EDTVRX, AGNActavis more inclined to pursue Allergan over Salix, says Citigroup
Subscribe for More Information
October 7, 2014
18:29 EDTAGN, VRXOn The Fly: After Hours Movers
Subscribe for More Information
18:05 EDTVRX, AGNValeant, Pershing Square plan to raise Allergan bid by $15 a share, WSJ says
Subscribe for More Information
17:52 EDTVRX, AGNAllergan up 2.8% after Dow Jones says Valeant planning to boost bid for company
17:49 EDTAGN, VRXValeant up 3.9% after Dow Jones says planning to boost Allergan bid
Subscribe for More Information
17:47 EDTVRX, AGNValeant, Pershing Square planning to boost Allergan bid by $15 a share, DJ says
Subscribe for More Information
15:21 EDTVRX, AGNAllergan warms to sale as Actavis plans new approach, Reuters says
Subscribe for More Information
15:01 EDTAGNAllergan up 1.5% following report on Actavis planned approach on merger
14:59 EDTAGNActavis plans new approach to Allergan, Reuters reports
Subscribe for More Information
07:48 EDTAGNSalix reinstated with a Buy at Jefferies
Subscribe for More Information
07:12 EDTVRX, AGNAllergan requests Ackman be hindered from voting at meeting, Bloomberg says
In an effort to avoid an unsolicited $54B acquisition offer from Valeant Pharmaceuticals (VRX), Allergan (AGN) filed a request in a California court for a judge to hinder Bill Ackmanís Pershing Square from voting its 10% stake at the December shareholder meeting, according to Bloomberg, citing the filing. A hearing regarding Allergan's request is set to occur on October 28. Reference Link
October 6, 2014
11:15 EDTAGNDurata surges after Actavis takeover
Shares of Durata Therapeutics (DRTX) are surging after the drugmaker agreed to be acquired by its larger industry peer, Actavis (ACT). WHAT'S NEW: Actavis announced it will commence a tender offer to acquire all of the outstanding shares of Durata common stock for $23.00 per share in cash, or approximately $675M in the aggregate, and contingent value rights entitling the holder to receive additional cash payments of up to $5.00 per share if certain regulatory or commercial milestones related to Durata's lead product Dalvance are achieved. If Dalvance is approved in Europe for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI, holders of the CVR will receive $1.00 per share. If Dalvance is approved for single dose administration by the FDA, holders of the CVR will receive $1.00 per share. If a net global Dalvance revenue threshold is met over a designated time period, holders of the CVR will receive $3.00 per share. Actavis expects the acquisition to be accretive by the end of the first year, it stated. WHAT'S NOTABLE: The acquisition comes after Durata Therapeutics was granted a Special Protocol Agreement by the FDA for its Phase 3 study of Dalvance on October 3. The study was designed to study Dalvance for the treatment of patients with community-acquired pneumonia and pediatric osteomyelitis. ANALYST REACTION: BMO Capital views the acquisition as a "good deal" for Actavis that is in line with CEO Brent Saunders' goal of making investments that complement its existing business. BMO believes the acquisition does not extend Actavis' balance sheet too far, and therefore does not prevent the company from doing additional deals. The firm expects there could be more deal-related news ahead for Actavis. The Fly notes Bloomberg reported on October 2 that Salix Pharmaceuticals (SLXP) was discussing selling itself to Actavis after failing to reach a deal with Allergan (AGN). PRICE ACTION: During morning trading, Durata Therapeutics gained $9.93, or 71.5%, to $23.81, Actavis slipped $1.95, or 0.8% to $244.12, and Salix fell $4.02, or 2.6%, to $148.85.
08:07 EDTAGNSalix slips in pre-market trade after Actavis strikes deal for Durata
Note that Bloomberg reported on October 2, citing people with knowledge of the matter, that Salix Pharmaceuticals (SLXP) was discussing selling itself to Actavis (ACT) after failing to reach a deal with Allergan (AGN). Actavis announced this morning that it has reached a deal to acquire Durata Therapeutics (DRTX) for $675M, or $23.00 per share. In pre-market trading, shares of Salix are down nearly 2% to $150 per share.
07:01 EDTAGNAllergan Q3 results likely to beat expectations, says Bernstein
Bernstein predicts that Allergan's Q3 EPS will exceed expectations by 15c, driven by cost cutting.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use